Quick Answer
XBiotech Inc. reported Cash and Equivalents of $125.55 million for fiscal year 2025.
XBiotech Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $125.55M | -27.3% |
| 2024 | $172.68M | -13.7% |
| 2023 | $200.02M | +27.2% |
| 2022 | $157.31M | -33.6% |
| 2021 | $236.98M | -0.2% |
| 2020 | $237.37M | -66.8% |
| 2019 | $714.59M | +4416.2% |
| 2018 | $15.82M | -50.2% |
| 2017 | $31.77M | -7.4% |
| 2016 | $34.32M | -62.3% |
| 2015 | $91.05M | +58.8% |
| 2014 | $57.33M | +691.4% |
| 2013 | $7.24M | +73.8% |
| 2012 | $4.17M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $147.37M | -19.5% | -3.6% |
| June 30, 2025 | $152.94M | -18.9% | -1.9% |
| March 31, 2025 | $155.90M | -22.5% | -9.7% |
| December 31, 2024 | $172.68M | -13.7% | -5.7% |
| September 30, 2024 | $183.12M | -9.4% | -2.9% |
| June 30, 2024 | $188.53M | +31.5% | -6.2% |
| March 31, 2024 | $201.04M | +31.8% | +0.5% |
| December 31, 2023 | $200.02M | +27.2% | -1.1% |
- XBiotech Inc. showed a decrease of -27.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, XBiotech Inc.’s cash and equivalents has grown by 2913.0% (from $4.17 million to $125.55 million).
- The most recent figure is from XBiotech Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: